Alkem Laboratories Ltd

Alkem Laboratories Limited informed the Bombay Stock Exchange and National Stock Exchange of India that its trading window will be closed from September 29, 2026, until 48 hours after the financial results for the quarter and half year ended September 30, 2026, are communicated to the stock exchanges, in accordance with the company’s insider trading regulations.

Alkem Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 5297, up 2.36% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.51% on the day, quoting at 23336.3. The Sensex is at 74608.42, up 0.37%. Alkem Laboratories Ltd has slipped around 3.25% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has slipped around 0.57% in last one month and is currently quoting at 26146.2, up 1.4% on the day. The volume in the stock stood at 78414 shares today, compared to the daily average of 1.33 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 5305, up 1.58% on the day. Alkem Laboratories Ltd is down 3.33% in last one year as compared to a 8.21% slide in NIFTY and a 17.44% slide in the Nifty Pharma index.The PE of the stock is 27.68 based on TTM earnings ending June 26.

Alkem Laboratories Limited announced the appointment of Dr. Shubhadeep Sinha to a senior management position, effective September 15, 2026, according to a regulatory filing with the Bombay Stock Exchange and National Stock Exchange of India. The duration of Dr. Sinha’s appointment will be for as long as he remains employed by the company, and he brings over 25 years of experience in clinical development, medical affairs, and regulatory affairs.

Alkem Laboratories Ltd share price declined by 0.94% to Rs 5418.75. The Company's net profit jumped 107.20% to Rs 521.49 crore, while revenue from operations slightly gained 3.80% to Rs 3740.15 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.69%. It has marginally improved by 0.66% over last one week and climbed by 11.20% in last one month while the market capitalization of Alkem Laboratories Ltd has softened by 3.76% and 1.21% in the same period respectively. Profit before tax (PBT) of Alkem Laboratories Ltd stood at Rs 771.99 crore in Q2 FY26, easing 0.13% year-on-year, and surging by 82.57% quarter-on-quarter. EBITDA came in at Rs 613 crore, gaining 1.78% YoY and rallying 93.27% sequentially. Total expenses marginally dropped 3.68% to Rs 3074.29 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 910.02 crore, posting a minor increase of 1.69% YoY, while employee benefits expense was at Rs 808.9 crore, surging 13.59% YoY. For the TTM ended FY26, revenue from operations rose 13.48% to Rs 14712.27 crore, while net profit grew slightly 6.19% to Rs 2353.13 crore, compared to previous TTM. EBITDA jumped by 204231% to Rs 2421.86 crore, and PBT improved 13.61% to Rs 2870.89 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1963.03 crore in FY26, as against Rs 1912.84 crore in FY25. Alkem Laboratories Ltd gained 0.52% in last one year, outperforming the benchmark BSE Sensex which has slipped by 3.05% during the same period.

Alkem Laboratories Limited informed the Bombay Stock Exchange and National Stock Exchange of India that the trading window will open on August 17, 2026, following the communication of the company's financial results for the quarter ended June 30, 2026, to the stock exchanges on August 14, 2026.

Alkem Laboratories Limited announced the appointment of Mr. Rajpal Singh Rana to a senior management position, effective August 3, 2026, according to a regulatory filing. Mr. Rana, who possesses over 30 years of experience in marketing and sales within the pharmaceutical sector, joins Alkem as Senior Vice President - Marketing & Sales, Acute Cluster, and holds an MBA in Marketing from Sikkim Manipal University and a B.Sc. from Delhi University.

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 14 August 2026.

Alkem Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 17 August 2026.

Alkem Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 5680, up 1.46% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.16% on the day, quoting at 24468.6. The Sensex is at 78452.78, up 0.21%. Alkem Laboratories Ltd has risen around 6.04% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has risen around 6.86% in last one month and is currently quoting at 25866.25, down 0.24% on the day. The volume in the stock stood at 1.28 lakh shares today, compared to the daily average of 1.58 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 5692.5, up 1.13% on the day. Alkem Laboratories Ltd is up 18.31% in last one year as compared to a 4.13% drop in NIFTY and a 16.41% drop in the Nifty Pharma index.The PE of the stock is 29.05 based on TTM earnings ending March 26.Powered by Capital Market - Live

Alkem Laboratories announced that the 52th Annual General Meeting(AGM) of the company will be held on 27 August 2026.